Sven Turkalj
@SvenTurkalj
Followers
202
Following
341
Media
3
Statuses
115
Postdoctoral Research Fellow in the Armstrong Lab at the @DanaFarber
Boston, MA
Joined February 2020
🔥Pre-print🔥 We show that therapy-resistant clones are selected within 1-3 cycles of IVO+VEN+/-AZA, months or years before relapse, within rare populations of persistent LSCs. Consistently, in patients with sustained remission, only WT/CH cells persist. https://t.co/2Q7rD7ZaeL
biorxiv.org
Acquired resistance to targeted non-intensive therapies is common in myeloid malignancies. Yet, key questions remain as to how rapidly resistant clones are selected by treatment and in which hemato...
2
6
26
Excited to see BoneMarrowMap out in press! Please check out the R package (now capable of classifying 100,000 hematopoietic cells in 10 minutes) and consider giving the paper a read for some insights into how differentiation goes wrong in AML!
Online now concurrent with #AACR25 #hematooncology Minisymposium talk by @andygxzeng and Dr. John Dick team @PMResearch_UHN: Single-cell transcriptional mapping reveals genetic and hierarchy-based determinants of aberrant differentiation in AML. https://t.co/gKNyA5rQpK
6
18
73
🔥New Fraticelli lab publication🔥 “Pre-existing stem cell heterogeneity dictates clonal responses to the acquisition of leukemia driver mutations” Two new figures compared to the pre-print, with more in vivo and sequential mutagenesis data. https://t.co/2MByy2tcO0
38
73
386
This work stems from a fantastic collaboration between the @vyas_lab and the MD Anderson team! Big thanks to @pvyas_oxford, Courtney D. DiNardo, @mkonople, Bilyana Stoilova, @angusgroom, @FARadtke, Rabea Mecklenbrauck, @CLachowiez, @sanamloghavi, and all other authors!
0
0
0
Importantly, our work highlights complex and diverse routes toward resistance to IVO+VEN+/-AZA, showing that different genetic clones are selected within distinct populations of LSCs. Future work should thus investigate how mutations confer advantage within these LSC populations.
1
0
0
Our work suggests early analysis of residual LSCs may identify patients destined to relapse and, in some cases, may allow to alter treatment, potentially improving survival of these high-risk patients. These notions hold important implications for Phase III trials of IVO+VEN+AZA.
1
0
0
Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy https://t.co/mBukYsYIu7
#biorxiv_cancer
0
2
6
So excited to present our work this Sunday in San Diego at #ASH2024! Very rapid clonal selection within BM populations known to harbor LSC activity foreshadows clinical outcome following IVO+VEN+/-AZA. A great collaboration between Oxford and the MD Anderson! Abstract 642 👇
1
1
8
🎉Excited to present our latest work out today @Nature 1.What gives a leukemia its phenotype – the oncogenic driver or the differentiation stage of the cell-of-origin? 2.Why do RAS mutations always happen late in AML? 3.Who will relapse after VEN?
nature.com
Nature - We find that RAS-mutant leukaemia stem cells are resistant to venetoclax, driving clinical resistance and relapse with monocytic features.
56
137
599
What role does epigenetic regulation play in hematopoietic stem cell fate? Drs. Yiran Meng and Claus Nerlov at @MRC_WIMM discuss our current understanding of the field, including chromatin accessibility, DNA methylation, and histone modifications. https://t.co/DuR7MQGqWP
0
3
11
Really pleased to share this clinically important collaborative study between UK AmML Clinical Trial Group and Hovon. The first of many future pan-European collaborative studies in AML and High risk MDS
Read the full study: https://t.co/8TM1pS4d3a. Special thanks to @pvyas_oxford and Peter Valk for leading this great UK-HOVON joint project. Many thanks to all collaborators to these clinical trials! #HOVON #NCRI. 🧵9/9
0
3
29
NEW: Research from the Nerlov & @vyas_lab in the @MCR_MHU has identified platelet-biased blood stem cells in humans for the first time, showing that this subtype of stem cells is a conserved feature of mammalian evolution. Read more: https://t.co/G8X7TKdDoS
0
4
8
🚨New Paper Alert🚨Excited to share our research on human HSC heterogeneity, now published in @SciImmunology! Check out the full paper here: https://t.co/HzC3PxdXeS. See some highlights below.
science.org
In vivo barcoding and single-cell RNA sequencing identifies platelet-biased human bone marrow HSCs.
8
9
61
Delighted to share our latest work performed in close collaboration with the Nerlov lab. Hematopoietic stem cell heterogeneity and age-associated platelet bias are evolutionarily conserved | Science Immunology
science.org
In vivo barcoding and single-cell RNA sequencing identifies platelet-biased human bone marrow HSCs.
9
17
101
Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging
cell.com
Vyas and colleagues show DNMT3A and TET2 mutation-specific patterns of clonal expansion in human clonal hematopoiesis (CH). Hematopoietic stem cells (HSCs) in CH bone marrow have heightened transcr...
0
12
39
Check the amazing tweetorial from @asger_jakobsen about our work on DNMT3A and TET2 mutant clonal hematopoiesis! 🧵👇
Mutant HSCs in human clonal haematopoiesis have an attenuated response to inflammation and ageing, which may give them a selective advantage. Happy to share our new paper published in @CellStemCell: https://t.co/TehWdhmkVw A thread below… /1
0
0
2
NEW: Study published in @CellStemCell by @vyas_lab, with the Dick and Xie labs at @pmcancercentre, uncovers key details of clonal outgrowth in blood cells with ageing. Read more: https://t.co/anIsqOi9sM Congrats to @asger_jakobsen, @SvenTurkalj, @pvyas_oxford & all authors!
0
7
19
There is strong selective pressure for CH mutations in #HSC, as a way to attenuate the impact of inflammation and aging. Such a wonderful collaboration with @pvyas_oxford and John Dick, driven by @asger_jakobsen @SvenTurkalj @andygxzeng. @MRC_WIMM @PMResearch_UHN
Excited to share: Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging: Cell Stem Cell https://t.co/bgUbM9kQfp Huge privilege to work colleagues in the lab and with Andy, Stephanie and John
7
7
41
Stem cell competition in human bone marrow. New study in @CellStemCell has found that resistance to inflammation gives mutated blood stem cells in human bone marrow a growth advantage over non-mutated stem cells. https://t.co/wGn08bTzVb
@stephxie @UHN_research @pvyas_oxford
0
7
24